Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

CohBar Inc
Healthcare
P/NCAV
0.28x
Ticker
CWBR
Exchange
Over The Counter
Country
United States
Close
0.9 $
Mkt Cap
2.6M $
EV
-3.6M $
NCAV Burn Rate
53.6%
Current Ratio
4.15
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.3x
EV/FCF
0.3x
Dilution
23.6% p.A
Total Net Income
-95.1M $
Cheapness
100.0%
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average